Logo

IP Update: Recent Patents Awarded to Tekmira, Quark, and More

Feb 06, 2014
Premium

Title: Lipid-containing Formulations

Patent Number: 8,642,076

Filed: Aug. 16, 2011

Lead Inventor: Muthiah Manoharan, Tekmira Pharmaceuticals (Alnylam Pharmaceuticals)

Title: Therapeutic Uses of Inhibitors of RTP801

Patent Number: 8,642,571

Filed: Aug. 31, 2012

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

Title: microRNA Inhibitors Comprising Locked Nucleotides

Patent Number: 8,642,751

Filed: Dec. 15, 2011

Lead Inventor: Christina Dalby, Miragen Therapeutics

Title: Detection of RNA in Tissue Samples

Patent Number: 8,644,580

Filed: Aug. 7, 2009

Inventor: David Lynch, Cambridge Research & Instrumentation

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
RNAi
miRNA
intellectual property
USPTO
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.